These findings are in agreement with an earlier study of 66 RA patients which reported decreases in circulating ACPA in a subgroup of early RA patients treated with various synthetic DMARDs, but which did not correlate with either treatment response or type of therapeutic agent [9]. Here, PRTN3 is linked to rheumatoid arthritis.